- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03385941
Radio-frequency Identification (RFID) Osteoporosis Pilot Study
RFID Osteoporosis Pilot Study
This examines in-vivo microwave sensing to measure a radio- frequency signal propagating through the wrist and, based on this information, establish a correlation of measured parameters with the integral bone density. This radio- frequency device is designed to obtain an integral estimate of bone density (osteoporotic vs normal).
The measurements can be done in three ways. The first method (Method 1) utilizes Received Signal Strength (RSS) of an RFID tag array at 915 megahertz located on the top of the wrist. The transmitting antenna located on the bottom of the wrist is connected to an RFID reader. In that way, the signal travels twice across the wrist: from the reader to the tag and vice versa.
The second method (Method 2) is to use only one transmitting antenna, connect the transmitting antenna to a portable Network Analyzer and measure the reflection coefficient, S11, of the antenna itself. This method does not imply that the entire signal will travel back and forth through the wrist, although its significant portion will. This method is, however, broadband and allows us to measure antenna resonances, which are very sensitive to the wrist composition.
The third method (Method 3) is to use both transmitting and receiving antennas, connect the antennas to a portable KeySight Network Analyzer and measure the transmission coefficient, S21, of the antenna pair. This method implies that the entire signal will travel through the wrist once. This method is also broadband and allows us to measure decay of the radio-signal in the wrist over a band of frequencies.
The two last methods could be combined together.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
In osteoporotic patients:
- 50-80 years of age
- Established diagnosis of osteoporosis, based on prior dual energy x-ray absorptiometry (DXA) scan with T-score <-2.0 at any site and/or history of fragility fracture
In healthy controls:
- 27-40 years of age
- Female
Exclusion Criteria:
In osteoporotic patients:
- Current or recent (within 2 years) use of osteoporosis medications including bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators, teriparatide, denosumab, calcitonin, or strontium
- Pregnancy or breastfeeding within the past 2 years
- Any medical or psychiatric condition or situation that would compromise subject safety, informed consent/assent, or data quality
In healthy controls:
- History of significant cardiac, renal, pulmonary, hepatic, or malignant disease, or current alcohol or illicit drug abuse
- Current diagnoses known to effect bone metabolism, including cystic fibrosis, diabetes, osteoporosis, amenorrhea >3 months (in menstruating women who are not taking oral contraceptives or have an IUD), hyperthyroidism, hyperparathyroidism, Paget's disease, kidney stones, chronic inflammatory diseases, malabsorptive disorders, malnutrition or eating disorder, endocrine disorders (growth disorder, Cushing syndrome), prolonged immobility, and skeletal dysplasias
- History one or more pathologic fracture, or greater than four total lifetime non-digital, non-facial fractures
- Cumulative lifetime use of oral glucocorticoids for greater than 2 months
- Current or previous use of medications known to affect bone metabolism including hormone replacement therapy, anti-estrogens, bisphosphonates, calcitonin, lithium, suppressive doses of levothyroxine, or anticonvulsants.
- Pregnancy or breastfeeding within the past 2 years
- BMI less than 18.5 or greater than 30 kg/m2.
- Any medical or psychiatric condition or situation that would compromise subject safety, informed consent/assent, or data quality
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Osteoporotic
Femal, 50-80 years of age with established diagnosis of osteoporosis, based on prior DXA scan with T-score <-2.0 at any site and/or history of fragility fracture
|
Non-osteoporotic
Female, 27-40 years of age, no established history of osteoporosis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Osteoporosis Screening through the use of a novel On-Body Passive Radio Frequency Identification (RFID) Array and corresponding test bed to include a receiving antenna.
Time Frame: Data from the testing will be available in near real-time and will be collated and reported on within 1 week of the assessment
|
A measurement will be performed to assess if a given patient is or is not at risk of osteoporosis.
The measurement is based on the received signal strength or power received from the RFID tag.
|
Data from the testing will be available in near real-time and will be collated and reported on within 1 week of the assessment
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017P001452
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Loss, Age Related
-
Fundació Institut de Recerca de l'Hospital de la...CompletedBone Loss, Age-Related
-
Fundación Santa Fe de BogotaInstituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)SuspendedBone Loss, Age-Related,
-
Institut National de la Santé Et de la Recherche...Merck Sharp & Dohme LLCCompletedBone Loss, Age-relatedFrance
-
University of California, San FranciscoJohns Hopkins UniversityCompleted
-
Astellas Pharma IncOno Pharmaceutical Co. LtdCompletedOsteoporosis | Bone Loss, Age-RelatedJapan
-
Australian Catholic UniversityCurtin University; Pendulum TherapeuticsActive, not recruitingGlucose Metabolism Disorders | Postmenopausal Osteopenia | Age-related Cognitive Decline | Age-Related Sarcopenia | Bone Loss, Age RelatedAustralia
-
Tufts UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedFall Injury | Muscle Loss | Fractures | Osteoporosis, Age RelatedUnited States
-
Mayo ClinicCompletedOsteoporosis | Postmenopausal Osteoporosis | Postmenopausal Bone Loss | Bone Loss, Age RelatedUnited States
-
Purdue UniversityUnknownOsteoporosis, Postmenopausal | Bone Loss, Age-relatedUnited States